{"entity":{"id":"nct06898450","kind":"trial","name":"A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.","aka":[],"tldr":"A phase 1/2 trial of NDI-219216 in advanced solid tumours, run by Nimbus Wadjet, Inc., now recruiting.","summary":"A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT06898450 by Nimbus Wadjet, Inc., with 134 participants planned, started 2025-03-31 and due to reach its primary completion in 2031-10. Interventions recorded: NDI-219216.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06898450","url":"https://clinicaltrials.gov/study/NCT06898450"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["ndi-219216"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06898450","phase":"1/2","setting":"A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 in Patients With Advanced Solid Tumors With/Without Microsatellite Instability and/or Deficient Mismatch Repair","sponsor":"Nimbus Wadjet, Inc.","enrolled":134,"outcomes":[]},"route":"/trials/nct06898450/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"ndi-219216","kind":"drug","name":"NDI-219216","route":"/drugs/ndi-219216/"}]}}